Introduction {#S0001}
============

In the past decade, a number of advances in the medical treatment and diagnosis of lung cancer have notably increased survival rates.[@CIT0001] Due to this development, the investigation of psychological outcomes as assessed via patient reported outcome measures in lung cancer patients becomes more and more relevant.[@CIT0002],[@CIT0003] Quite a few studies even showed that QOL is a positive predictor of survival in lung cancer patients.[@CIT0004]--[@CIT0008] Therefore, understanding determinants of the psychological outcomes such as QOL is crucial in order to maximize QOL and consequently survival.

One of the most promising psychological concepts that is related to various illness outcomes in chronic patients appears to be illness perceptions (IPs). IPs are the cognitive and emotional responses of patients to their illness and its medical management.[@CIT0009] IPs do not necessarily reflect "medically correct facts" and differ quite substantially from accepted medical wisdom. In line with the assumptions of the common-sense model of self-regulation of health and illness,[@CIT0009] various empirical studies showed that IPs have an impact on illness outcomes, such as functional health and QOL, directly and indirectly via illness behavior.[@CIT0010]--[@CIT0012] Therefore, addressing IPs and attempting to change them can contribute to the overall well-being of patients.

The aim of the current paper is to investigate the course of IPs and psychological outcomes, ie, functional health and QOL, in lung cancer patients over a 3-month period during chemotherapy. Moreover, the relationships between illness perceptions and psychological outcomes is examined.

Methods {#S0002}
=======

The presented data are part of a larger international, bicenter study on illness perceptions and QOL in cancer patients.[@CIT0013] The study was conducted in line with the Helsinki Declaration. The study protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center, the Netherlands (\#P12-090) and written informed consent was obtained from all participants.

Procedure {#S0002-S2001}
---------

Patients were recruited in the Leiden University Medical Center, the Netherlands. Patients were included if they had the diagnosis of non-small-cell lung carcinoma (NSCLC) of any stage and were undergoing first-line adjuvant or neo-adjuvant chemotherapy. Patients with EGFR or ALK mutations and patients undergoing concurrent radiotherapy and chemotherapy were excluded, in order to obtain a homogenous sample regarding clinical characteristics and type of therapy.

Data were collected at two-time points, ie, at the beginning of the treatment, approximately 12 days after the first round of chemotherapy and 1 month after the last round of chemotherapy, approximately 3 months later.

Measures {#S0002-S2002}
--------

The Dutch version of Brief Illness Perception Questionnaire (Brief IPQ)[@CIT0014] was used to measure five cognitive illness perceptions (ie, consequences, timeline, personal control, treatment control, identity), two emotional illness perceptions (ie, concern, emotions) and illness comprehensibility with one item each (range 0--10). Higher scores indicate stronger perceptions that lung cancer affects the life, has a long duration, can be controlled by own behavior or medical treatment, involves much complaints, elicits concerns, produces negative emotions, and is understandable.

The Dutch version of the EORTC Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30)[@CIT0015] was used to assess functional health and global QOL. Functional health was measured with 15 items that were combined into five subscales, ie, physical, role, emotional, cognitive, and social functioning. Global QOL was measured with two items. All subscales were linearly transformed (range 0 to 100), with higher scores indicating better functional health and higher QOL.

Participants {#S0002-S2003}
------------

Thirty patients were included and completed the baseline measurement. Of these, nine patients did not return the follow-up questionnaires, which resulted in a final sample of 21 patients (female: n=13, 61.9%). The sample included 1 patient (4.8%) with stage IIA, 2 patients (9.5%) with stage IIB, 5 patients (23.8%) with stage IIIA, and 13 patients (61.9%) with stage IV non-small-cell lung carcinoma. Most patients (n=17, 81.0%) had no comorbidity. The mean age of the patients was 64.62 years (*SD*=7.70; range 53--82 years).

Data Analyses {#S0002-S2004}
-------------

Due to the small sample size, the data were analyzed by using nonparametric statistical tests. To explore the course of IPs, functional health, and QOL throughout chemotherapy, Wilcoxon signed-rank tests comparing scores at baseline with scores at follow-up were computed. The relationships between IPs at baseline and functional health and QOL at baseline and at follow-up were examined by means of Kendall's tau-b correlations. Due to the small sample size and consequently suboptimal power, significance from *p*\<0.10 is reported and the effect size was taken into account when interpreting the results.

Results {#S0003}
=======

IPs, Functional Health, and QOL at Baseline and Follow-Up {#S0003-S2001}
---------------------------------------------------------

[Table 1](#T0001){ref-type="table"} (upper part) shows some small changes in IPs between baseline and follow-up. After the chemotherapy, patients reported less perceived consequences, less personal control, less experienced symptoms, and less concern compared to the beginning of the chemotherapy. These changes seem to be discernible also on a few dimensions of functional health. Emotional and cognitive functioning improved moderately and slightly, respectively (lower part [Table 1](#T0001){ref-type="table"}).Table 1Comparisons of Illness Perceptions, Functional Health, and Quality of Life at Baseline and Follow-Up (Wilcoxon Signed-Rank Test)N^a^M (SD) Md BaselineM (SD) Md Follow-UpZ (r^b^)Illness Perceptions Consequences206.60 (2.95) 8.005.65 (2.81) 6.00−1.13 (0.25) Timeline196.37 (2.61) 5.006.79 (3.01) 7.00−0.52 (0.12) Personal control204.68 (3.01) 5.004.00 (2.90) 4.00−1.31 (0.29) Treatment control207.70 (1.75) 8.007.65 (2.03) 8.00−0.20 (0.04) Identity205.20 (2.61) 5.003.75 (2.69) 5.00−1.68^(^\*^)^ (0.38) Concern196.26 (2.77) 7.005.32 (2.91) 5.50−1.19 (0.27) Understanding197.53 (2.34) 8.007.21 (2.02) 7.50−0.55 (0.13) Emotions204.80 (3.05) 4.004.45 (2.78) 4.0−0.61 (0.14)Functional Health and Quality of Life Physical functioning2174.29 (19.47) 80.0071.19 (18.19) 73.34−0.97 (0.21) Role functioning2160.32 (26.07) 66.6753.17 (31.89) 50.00−0.84 (0.18) Emotional functioning2173.02 (24.57) 83.3481.35 (22.96) 83.34−1.99\* (0.43) Cognitive functioning2178.57 (24.80) 83.3483.33 (16.67) 83.34−0.98 (0.21) Social functioning2173.81 (21.46) 83.3471.43 (26.43) 83.34−0.18 (0.04) Global QOL2159.52 (23.76) 66.6763.10 (18.55) 66.67−0.24 (0.05)[^1]

Relationships Between IPs and Functional Health and QOL {#S0003-S2002}
-------------------------------------------------------

[Table 2](#T0002){ref-type="table"} shows a large number of meaningful relationships of IPs at baseline with functional health and global QOL at baseline and follow-up. The IPs consequences, timeline, personal control, identity, concern, and understanding showed the most and the strongest correlations with various dimensions of functional health and QOL at both measurement points.Table 2Kendall's Tau-b Correlations Between Illness Perceptions at Baseline and Functional Health and Quality of Life at Baseline and Follow-UpPhysical Functioning Baseline/Follow-UpRole Functioning Baseline/Follow-UpEmotional Functioning Baseline/Follow-UpCognitive Functioning Baseline/Follow-UpSocial Functioning Baseline/Follow-UpGlobal QOL Baseline/Follow-UpConsequences−0.56\*\*−0.31^(^\*^)^−0.39\*−0.37\*−0.35^(^\*^)^−0.01−0.42\*−0.31−0.39\*−0.41\*−0.25−0.15Timeline−0.31^(^\*^)^−0.39\*−0.13−0.32^(^\*^)^−0.080.05−0.31^(^\*^)^−0.17−0.08−0.42\*−0.03−0.07Personal control−0.08−0.01−0.30^(^\*^)^−0.22−0.22−0.27−0.27−0.12−0.21−0.40\*−0.26−0.10Treatment control0.34^(^\*^)^−0.080.33^(^\*^)^−0.020.18−0.020.38\*0.300.01−0.150.41\*−0.16Identity−0.62\*\*\*−0.18−0.58\*\*−0.04−0.31^(^\*^)^−0.08−0.36^(^\*^)^−0.08−0.18−0.09−0.69\*\*\*−0.07Concern−0.42\*−0.08−0.29−0.15−0.41\*−0.14−0.36^(^\*^)^−0.11−0.15−0.19−0.52\*\*−0.05Understanding−0.01−0.38\*−0.04−0.40\*−0.09−0.16−0.130.070.10−0.39\*−0.15−0.34^(^\*^)^Emotions−0.19−0.01−0.49\*\*−0.20−0.15−0.10−0.240.01−0.12−0.18−0.44\*−0.35\*[^2]

Discussion {#S0004}
==========

IPs and psychological outcomes of our patients at the beginning of the chemotherapy are comparable to earlier findings in lung cancer patients.[@CIT0013] Previous research showed that chemotherapy negatively affects the generalized health-related quality of life.[@CIT0016] We expand this finding by showing that IPs become slightly more positive and aspects of functional health slightly increase after chemotherapy. Interestingly, in the present study, QOL seems not to improve after chemotherapy.

At the beginning of chemotherapy, IPs were significantly associated with various aspects of functional health and QOL. More importantly, IPs at the beginning of chemotherapy were also prospectively related to these outcome measures after chemotherapy. Specifically, the perception of more serious consequences, a longer timeline, more personal control, more negative emotions, and a better understanding of lung cancer predict lower functional health and QOL. These findings are largely in line with previous research in cancer patients,[@CIT0017] except from the remarkable finding that a better understanding of lung cancer has a negative effect on the outcome measures.

Conclusion and Future Directions {#S0005}
================================

The number of respondents in our study must be deemed to be rather small. Patients in whom NSCLC has been diagnosed become quite ill quite soon, and they find it burdensome to fill out questionnaires, limiting empirical studies on quality of life (in a broad sense) in these patients.[@CIT0018]--[@CIT0020] Despite this limitation, our findings suggest that IPs of lung cancer patients play an important role in functional health and QOL, and should therefore be taken into consideration during medical treatment. Communicating about emotions and concerns seems to be most critical.[@CIT0021] Purely providing patients with clinical information in order to satisfy their information needs[@CIT0022] without discussing psychosocial issues[@CIT0023] might be detrimental as our findings indicate that a better understanding of lung cancer worsens functioning and QOL in the long run. Teaching physicians to address, discuss and help adjust unhelpful illness perceptions in patients with NSCLC leads to less adjustment problems in the patients and their caregivers.[@CIT0024],[@CIT0025] Future studies with larger sample sizes should investigate whether addressing IPs in lung cancer patients impact on patient related outcome measures.
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[^1]: **Notes:** ^a^N varies due to missing data. ^b^Effect size *r* = Z/√N. *r*≥0.1 = small effect, *r*≥0.3 = medium effect, *r*≥0.5 = large effect. \**p*\<0.05, ^(^\*^)^*p*\<0.10.

[^2]: **Notes:** N ranges between 19 and 20 due to missing data. *τ~b~*≥0.1 = small effect, *τ~b~*≥0.3 = medium effect, *τ~b~*≥0.5 = large effect. \*\*\**p*\<0.001, \*\**p*\<0.01, \**p*\<0.05, ^(^\*^)^*p*\<0.10.
